PP
LCTX icon

Pacifica Partners’s Lineage Cell Therapeutics LCTX Stock Holding History

Pacifica Partners’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.92K Hold
2,926
– – ﹤0.01% 360
2026
Q1 		$4.62K Hold
2,926
– – ﹤0.01% 362
2025
Q4 		$4.8K Hold
2,926
– – ﹤0.01% 340
2025
Q3 		$4.97K Hold
2,926
– – ﹤0.01% 384
2025
Q2 		$2.74K Hold
2,926
– – ﹤0.01% 450
2025
Q1 		$1.22K Hold
2,926
– – ﹤0.01% 476
2024
Q4 		$1.51K Hold
2,926
– – ﹤0.01% 444
2024
Q3 		$2.65K Hold
2,926
– – ﹤0.01% 442
2024
Q2 		$2.67K Hold
2,926
– – ﹤0.01% 451
2024
Q1 		$3.71K Hold
2,926
– – ﹤0.01% 430
2023
Q4 		$2.93K Hold
2,926
– – ﹤0.01% 470
2023
Q3 		$3.83K Hold
2,926
– – ﹤0.01% 433
2023
Q2 		$3.95K Hold
2,926
– – ﹤0.01% 390
2023
Q1 		$4.05K Hold
2,926
– – ﹤0.01% 404
2022
Q4 		$3.08K Hold
2,926
– – ﹤0.01% 397
2022
Q3 		$4K Hold
2,926
– – ﹤0.01% 384
2022
Q2 		$4K Hold
2,926
– – ﹤0.01% 390
2022
Q1 		$4K Hold
2,926
– – ﹤0.01% 386
2021
Q4 		$6K Hold
2,926
– – ﹤0.01% 352
2021
Q3 		$8K Hold
2,926
– – 0.01% 317
2021
Q2 		$8K Hold
2,926
– – 0.01% 308
2021
Q1 		$7K Hold
2,926
– – 0.01% 298
2020
Q4 		$5K Hold
2,926
– – ﹤0.01% 297
2020
Q3 		$3K Hold
2,926
– – ﹤0.01% 297
2020
Q2 		$2K Hold
2,926
– – ﹤0.01% 339
2020
Q1 		$2K Hold
2,926
– – ﹤0.01% 328
2019
Q4 		$3K Buy
+2,926
New +$2.44K ﹤0.01% 313

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Pacifica Partners's LCTX Position: Q2 2026 in Review

Pacifica Partners held its Lineage Cell Therapeutics (LCTX) position steady in Q2 2026 at 2,926 shares worth $3.92K. The position accounts for ﹤0.01% of the portfolio, ranked #360.

Pacifica Partners first reported a position in LCTX in Q4 2019 and has held it in 27 quarters since. The position peaked at $8K in Q3 2021. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • Pacifica Partners held 2,926 shares of Lineage Cell Therapeutics worth $3.92K as of Q2 2026.
  • Pacifica Partners left its Lineage Cell Therapeutics share count unchanged in Q2 2026.
  • Lineage Cell Therapeutics made up ﹤0.01% of Pacifica Partners's portfolio in Q2 2026, its #360 holding.
  • Pacifica Partners first reported a position in Lineage Cell Therapeutics in Q4 2019 and has held it in 27 quarters since.
  • Pacifica Partners's Lineage Cell Therapeutics position peaked at $8K in Q3 2021.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Pacifica Partners's 13F filing for Q2 2026, filed 13 Jul 2026.